Christelle Dupouy

Christelle Dupouy

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 May 2006 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
CDChristelle Dupouy
Christelle Dupouy
NINathalie Iché‐Tarrat
Nathalie Iché‐Tarrat
MDMarie‐Pierre Durrieu
Marie‐Pierre Durrieu
FRFrederic RODRIGUEZ
Frederic RODRIGUEZ
JEJean-Marc Escudier
Jean-Marc Escudier
AVAlain Vigroux
Alain Vigroux

16 June 2011 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
TLThomas Lavergne
Thomas Lavergne
CBCarine Baraguey
Carine Baraguey
CDChristelle Dupouy
Christelle Dupouy
NPNora Parey
Nora Parey
WWWinfried Wuensche
Winfried Wuensche
FDFrançoise Debart
Françoise Debart

19 February 2018 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
FDFrançoise Debart
Françoise Debart
CDChristelle Dupouy
Christelle Dupouy
JVJean Jacques Vasseur
Jean Jacques Vasseur
Oligonucleotides (ONs) have been envisaged for therapeutic applications for more than thirty years. However, their broad use requires overcoming several hurdles such as instability in biological fluids, low cell penetration, limited tissue distribution, and off-target effects. With this aim, many chemical modifications have been introduced into ONs definitively as a means of modifying and better improving their properties as gene silencing agents and some of them have been successful. Moreover, in the search for an alternative way to make efficient ON-based drugs, the general concept of prodrugs was applied to the oligonucleotide field. A prodrug is defined as a compound that undergoes transformations in vivo to yield the parent active drug under different stimuli. The interest in stimuli-responsive ONs for gene silencing functions has been notable in recent years. The ON prodrug strategies usually help to overcome limitations of natural ONs due to their low metabolic stability and poor delivery. Nevertheless, compared to permanent ON modifications, transient modifications in prodrugs offer the opportunity to regulate ON activity as a function of stimuli acting as switches. Generally, the ON prodrug is not active until it is triggered to release an unmodified ON. However, as it will be described in some examples, the opposite effect can be sought.This review examines ON modifications in response to various stimuli. These stimuli may be internal or external to the cell, chemical (glutathione), biochemical (enzymes), or physical (heat, light). For each stimulus, the discussion has been separated into sections corresponding to the site of the modification in the nucleotide: the internucleosidic phosphate, the nucleobase, the sugar or the extremities of ONs. Moreover, the review provides a current and detailed account of stimuli-responsive ONs with the main goal of gene silencing. However, for some stimuli-responsive ONs reported in this review, no application for controlling gene expression has been shown, but a certain potential in this field could be demonstrated. Additionally, other applications in different domains have been mentioned to extend the interest in such molecules.

1 December 2006 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
CDChristelle Dupouy
Christelle Dupouy
ICIngrid Le Clézio
Ingrid Le Clézio
PLPierre Lavedan
Pierre Lavedan
HGHeinz Gornitzka
Heinz Gornitzka
JEJean-Marc Escudier
Jean-Marc Escudier
AVAlain Vigroux
Alain Vigroux

1 December 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CDChristelle Dupouy
Christelle Dupouy
CZChi Zhang
Chi Zhang
APANDRE PADILLA
ANDRE PADILLA
SPSylvie Pochet
Sylvie Pochet
PKPierre Alexandre Kaminski
Pierre Alexandre Kaminski
Rcl is a potential anti-angiogenic therapeutic target that hydrolyzes the N-glycosidic bond of 2′-deoxyribonucleoside 5′-monophosphate, yielding 2-deoxyribose 5-phosphate and the corresponding base. Its recently elucidated solution structure provided the first insight into the molecular basis for the substrate recognition. To facilitate the development of potent and specific inhibitors of Rcl, the active site was probed by site-directed mutagenesis and by the use of substrate analogs. The nucleobase shows weak interactions with the protein, and the deoxyribose binding pocket includes the catalytic triad Tyr-13, Asp-69, and Glu-93 and the phosphate binding site Ser-87 and Ser-117. The phosphomimetic mutation of Ser-17 to Glu prevents substrate binding and, thus, abolishes the activity of Rcl. The synthetic ligand-based analysis of the Rcl binding site shows that substitutions at positions 2 and 6 of the nucleobase as well as large heterocycles are well tolerated. The phosphate group at position 5 of the (deoxy)ribose moiety is the critical binding determinant. This study provides the roadmap for the design of small molecules inhibitors with pharmacological properties.